IgGenix, Inc.
- Biotech or pharma, therapeutic R&D
IgGenix is a clinical-stage, venture backed company using single cell transcriptomics to isolate rare IgE producing B cells directly from patients and discover novel antibody therapeutics. Our lead program for peanut allergy is in P1 POC study with a readout in the second half of 2025. We are seeking new investors for our upcoming Series C, as well as partnerships for our platform and allergy programs.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}